You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Colorcon
McKesson
Harvard Business School
AstraZeneca

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,399,040

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,399,040 protect, and when does it expire?

Patent 9,399,040 protects OMIDRIA and is included in one NDA.

Protection for OMIDRIA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has twenty-eight patent family members in fourteen countries.

Summary for Patent: 9,399,040
Title:Ophthalmologic irrigation solutions and method
Abstract: Solutions for perioperative intraocular application by continuous irrigation during ophthalmologic procedures are provided. These solutions include multiple agents that act to inhibit inflammation, inhibit pain, effect mydriasis (dilation of the pupil), and/or decrease intraocular pressure, wherein the multiple agents are selected to target multiple molecular targets to achieve multiple differing physiologic functions, and are included in dilute concentrations in a balanced salt solution carrier.
Inventor(s): Demopulos; Gregory A. (Mercer Island, WA), Palmer; Pamela Pierce (San Francisco, CA), Herz; Jeffrey M. (Mill Creek, WA)
Assignee: Omeros Corporation (Seattle, WA)
Application Number:14/075,588
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,399,040
Patent Claim Types:
see list of patent claims
Composition; Formulation; Delivery;

Drugs Protected by US Patent 9,399,040

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Omeros OMIDRIA ketorolac tromethamine; phenylephrine hydrochloride SOLUTION;IRRIGATION 205388-001 May 30, 2014 AT RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,399,040

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2003261304   Start Trial
Australia 2009248461   Start Trial
Australia 2013202330   Start Trial
Australia 2016201834   Start Trial
Australia 2018200887   Start Trial
Canada 2493581   Start Trial
Canada 2866848   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Harvard Business School
McKesson
Moodys
Baxter
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.